Proceeds to be used to continue to advance development of Armata’s phage product candidates
Armata Pharmaceuticals, Inc. a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. Armata’s largest shareholder. The gross proceeds to be received by the Company at closing are $10 million before deducting transaction-related expenses.
Health Technology Insights: Amino Health Partners with Bend Health to Boost Youth Mental Health
Proceeds from the new financing transaction will be used to advance the Company’s lead therapeutic phage candidates, including AP‐PA02 and AP‐SA02, which target infections caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively.
“Innoviva continues to be an instrumental partner to Armata in support of our mission, the clinical development of our two lead phage cocktails, AP-PA02 and AP-SA02, and our committed team,” stated Dr. Deborah Birx, Chief Executive Officer of Armata. “This financing will enable Armata to readout its Phase 1b/2a trial in acute Staphylococcus aureus bacteremia, which represents the first clinical trial for AP-SA02, and to prepare the Company for an end-of-Phase 2 meeting with the FDA in support of further clinical inquiry including a potential pivotal trial. I would like to thank the Innoviva team for their continued support. We are continuing to pursue additional sources of funding, including non-dilutive sources, to support our late-stage clinical trials.”
Health Technology Insights: Propel Software Data Shows Growing Reliance on Medical Devices
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – PR Newswire
